Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.704 EUR | +2.07% |
|
-9.25% | -18.07% |
Jun. 19 | Evotec SE, Q1 2025 Earnings Call, May 06, 2025 | |
Jun. 17 | EVOTEC : Warburg Research reiterates its Buy rating | ZD |
Capitalization | 1.17B 1.34B 1.1B 996M 1.84B 116B 2.07B 12.93B 4.99B 52.93B 5.02B 4.91B 195B | P/E ratio 2025 * |
-14.3x | P/E ratio 2026 * | -36.5x |
---|---|---|---|---|---|
Enterprise value | 1.33B 1.53B 1.25B 1.14B 2.1B 133B 2.37B 14.76B 5.7B 60.42B 5.73B 5.61B 223B | EV / Sales 2025 * |
1.56x | EV / Sales 2026 * | 1.45x |
Free-Float |
88.77% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Evotec SE
EVOTEC : Warburg Research reiterates its Buy rating | Jun. 17 | ZD |
EVOTEC : RBC reiterates its Buy rating | May. 15 | ZD |
EVOTEC : Deutsche Bank gives a Neutral rating | May. 07 | ZD |
EVOTEC : Warburg Research keeps its Buy rating | May. 06 | ZD |
RBC leaves Evotec at 'Outperform' - target €11.60 | May. 06 | DP |
More press releases
More news
1 day | +1.40% | ||
1 week | -13.58% | ||
Current month | -5.52% | ||
1 month | -6.28% | ||
3 months | +0.12% | ||
6 months | -21.01% | ||
Current year | -19.85% |
1 week | 6.57 | ![]() | 7.48 |
1 month | 6.57 | ![]() | 8.57 |
Current year | 5.06 | ![]() | 9.33 |
1 year | 5.06 | ![]() | 10.62 |
3 years | 5.06 | ![]() | 29.71 |
5 years | 5.06 | ![]() | 45.83 |
10 years | 2.86 | ![]() | 45.83 |
Manager | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 2024-06-30 | |
Director of Finance/CFO | - | 2025-02-28 | |
Cord Dohrmann
CTO | Chief Tech/Sci/R&D Officer | 61 | 2010-08-31 |
Director | Title | Age | Since |
---|---|---|---|
Chairman | 64 | 2021-06-14 | |
Roland Sackers
BRD | Director/Board Member | 57 | 2019-06-18 |
Director/Board Member | 63 | 2021-05-31 |
Name | Weight | AuM | 1st Jan change | |
---|---|---|---|---|
2.59% | 0 M€ | -.--% | - | |
0.21% | 0 M€ | -.--% | - |
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
-4.12% | -13.58% | -10.46% | -71.62% | 1.34B | ||
-0.29% | -4.35% | +17.87% | +12.23% | 48.12B | ||
-0.45% | -8.53% | +63.51% | +91.43% | 29.99B | ||
-18.96% | +293.44% | +58,645.35% | +5,549.30% | 31.33B | ||
+0.33% | -2.84% | -27.36% | -21.50% | 26.75B | ||
-1.29% | -2.26% | -4.61% | +18.91% | 25.65B | ||
-1.75% | -1.62% | +13.39% | -19.28% | 12.25B | ||
-1.48% | -3.03% | +127.74% | - | 11.96B | ||
+1.11% | -2.49% | -54.99% | -28.60% | 11.41B | ||
-1.27% | -0.12% | +38.57% | +103.42% | 10.31B | ||
Average | -2.26% | +25.52% | +5,880.90% | +626.03% | 20.91B | |
Weighted average by Cap. | -3.27% | +40.48% | +8,802.06% | +900.33% |
2025 * | 2026 * | |
---|---|---|
Net sales | 853M 978M 801M 728M 1.34B 84.92B 1.51B 9.45B 3.65B 38.69B 3.67B 3.59B 142B | 939M 1.08B 882M 802M 1.48B 93.55B 1.67B 10.41B 4.02B 42.62B 4.04B 3.96B 157B |
Net income | -81.21M -93.13M -76.29M -69.38M -128M -8.09B -144M -900M -348M -3.69B -350M -342M -13.57B | -29.86M -34.24M -28.05M -25.51M -47.03M -2.97B -53.06M -331M -128M -1.35B -128M -126M -4.99B |
Net Debt | 165M 189M 155M 141M 260M 16.43B 293M 1.83B 706M 7.49B 710M 695M 27.58B | 200M 229M 188M 171M 315M 19.92B 355M 2.22B 856M 9.08B 861M 842M 33.43B |
More financial data
* Estimated data
Employees
4,766
Calendar
Jun. 24
- Antibody Industrial Symposium
Date | Price | Change | Volume |
---|---|---|---|
25-06-20 | 6.714 € | +2.22% | 134,645 |
25-06-19 | 6.568 € | -4.12% | 499,686 |
25-06-18 | 6.850 € | -2.14% | 1,128,616 |
25-06-17 | 7.000 € | -1.69% | 701,920 |
25-06-16 | 7.120 € | -3.76% | 992,098 |
Delayed Quote Xetra, June 19, 2025 at 11:40 am EDT
More quotesSell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
6.568EUR
Average target price
11.32EUR
Spread / Average Target
+72.43%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- EVT Stock
Select your edition
All financial news and data tailored to specific country editions